Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

53.31 +0.32 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,650,739
Open 53.05
Bid (Size) 52.50 (500)
Ask (Size) 54.00 (200)
Prev. Close 52.99
Today's Range 52.58 - 53.33
52wk Range 50.76 - 73.51
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth... 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-19.8%
-19.8%
1 Month
-3.6%
-3.6%
3 Month
-1.4%
-1.4%
6 Month
-5.2%
-5.2%
1 Year
-19.5%
-19.5%

More News

Read More
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
2 Reasons to Like BMRN and 1 to Stay Skeptical
Via StockStory
Topics Stocks
News headline image
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy Government World Trade
News headline image
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
Via StockStory
News headline image
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Cash-Producing Stocks with Promising Prospects
Via StockStory
News headline image
This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
Via Benzinga
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗
Via The Motley Fool
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
Via StockStory
Topics Earnings Economy Government
News headline image
Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings ↗
Via Benzinga
News headline image
BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook
Via StockStory
News headline image
BioMarin (BMRN) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss ↗
Via Chartmill
Topics Earnings
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates
Via StockStory
News headline image
Earnings Scheduled For October 27, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 53.31
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 12/12/25 04:00 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 9.77B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.